Sleep study comparing two HIV medicines: dolutegravir vs doravirine
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This trial compares the effects of two HIV medications (dolutegravir and doravirine) on sleep quality in people living with HIV. If you are between 18 and 40, have undetectable virus, and have been on your current HIV treatment for at least 6 months, this study may help find which medicine is better for sleep.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 40 years old.
- You have HIV and your viral load is undetectable (below 50 copies/mL).
- You have been on your current HIV treatment for at least 12 months, and on a specific regimen containing tenofovir, emtricitabine or lamivudine, and dolutegravir for at least 6 months.
- Your body mass index (BMI) is under 35 and you weigh more than 35 kilograms.
- You are willing to stay overnight for a sleep test (polysomnography).
- You do not have a known sleep disorder (like sleep apnea, insomnia, or restless legs) or take medications that affect sleep.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two HIV medications, dolutegravir and darunavir/cobicistat, to see which causes fewer brain-related side effects like sleep, mood, or anxiety issues. It is for adults starting HIV treatment for the first time.
This study compares two HIV medicines, doravirine and dolutegravir, to see which works better for people who have never taken HIV treatment before. If you qualify, you would be randomly assigned to one of the two medications.
This trial compares a two-drug regimen of doravirine and lamivudine to another two-drug regimen of dolutegravir and lamivudine for people with HIV who have had a suppressed viral load for at least 24 months. The goal is to see if the newer combination works as well as the current one.
This Phase 2 trial studies whether switching to a combination of doravirine and raltegravir can safely maintain control of HIV in adults whose virus is already well suppressed. It may help people who are currently on stable HIV treatment and are not resistant to these specific medicines.
This Phase 3 study tests whether switching from a three-drug HIV regimen to a two-drug regimen (doravirine plus dolutegravir) can keep your virus levels controlled. It may help people who are stable on their current treatment explore a simpler switch under close monitoring.
This study tests a fast-start HIV treatment using doravirine, tenofovir, and lamivudine for people who were just diagnosed with HIV in the last 30 days and have never taken HIV medications before. The goal is to see if starting treatment right away is safe and effective.
Hear when a new HIV (Human Immunodeficiency Virus) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.